King Deal Viewed As Key Driver For Mylan's Branded Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan believes that the King acquisition is the right strategy to expand its branded franchise
You may also be interested in...
Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol
The company cites King’s 1,200-person sales force as one reason behind the acquisition. King’s cardiovascular marketing experience with the ACE inhibitor Altace will be beneficial as Mylan anticipates approval for its beta blocker nebivolol.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.